The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity.
Betensky D, Smith K, Katz J, Yang C, Hunter D, Collins J, Feldman C, Messier S, Kim J, Selzer F, Paltiel A, Losina E. The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals Of Internal Medicine 2025 PMID: 40953447, DOI: 10.7326/annals-24-03609.Peer-Reviewed Original ResearchQuality-adjusted life yearsBody mass indexIncremental cost-effectiveness ratioKnee osteoarthritisWestern Ontario and McMaster Universities Osteoarthritis Index pain scorePain reductionBaseline body mass indexQuality-adjusted life year thresholdsHealth benefitsMicrosimulation modelWeight loss strategiesCost-effectiveMean body mass indexUsual careHealth policyCost-effectiveness thresholdOsteoarthritis Policy ModelCost-effectiveness ratioGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsLife yearsBase-case cohortMass indexLoss strategiesMedical costs
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply